QUARKS - Lebensqualität und Resilienz bei KMT-Patienten Studie

Allogeneic stem cell transplantation (alloSCT) can be a very taxing treatment. Besides somatic factors, psychosocial variables need to be considered in order to optimize the benefit from this treatment for patients.

This longitudinal study at the University Hospital Muenster, Germany, assesses the quality of life (QL), anxiety, depression and resilience in patients undergoing alloSCT at 3 time-points: beginning (T1) and end (T2) of inpatient treatment and 6 months after discharge (T3). The sample includes 65 patients (mainly leukemia, lymphoma, myeloma), aged 20-76 years. The instruments EORTC QLQ-C30, HADS, and Resilience Scale RS-25 are used. A semi-structured interview one year after alloSCT focuses on patients’ perception of their treatment.


PD Dr. Andrea Schumacher, Department of Medicine A / Hematology and Oncology

Beteiligte Wissenschaftler:

Dipl.-Math. C. Sauerland, Dr. rer. medic. R. Koch, Dipl.-Math.